HOW TO STUDY EPIGENETIC MODIFICATIONS

-- STRATEGIES USING SUV39H1 AS A HALLMARK MODEL FOR EPIGENTIC REGUALTION --

Chromatin comes in different flavors

Different types of chromatin

- constitute \sim 10% of nuclear DNA; telomeres, centromeres, and a considerable fraction of repetitive sequences
- highly compacted, replicates late in S phase, (transcriptionally inert)

Euchromatin + facultative heterochromatin:

- constitute \sim 90% of nuclear DNA
- less condensed, rich in genes, replicates early in S phase **however**,
- only small fraction of euchromatin is transcriptionally active
- the rest is transcriptionally inactive/silenced (but can be activated in certain tissues or developmental stages) \rightarrow these inactive regions are also known as "facultative heterochromatin"

Chromocenter (aggregates of centromeres = constitutive heterochromatin)

(and facultative heterochromatin)

Post-translational histone modifications can recruit specialized proteins

Example: SUV39H1 and HP1 form heterochromatin at centromeric and telomeric Heterochromatin in flies and vertebrates and SAHFs

cells and can be visualized by immunofluorescence

Post-translational histone modifications can recruit specialized proteins

Example: SUV39H1 and HP1 form heterochromatin at centromeric and telomeric Heterochromatin in flies and vertebrates and SAHFs

OIS: Oncogene induced senescence

A historical view: how to understand the enzymatic function of an epigenetic writer Histones can be acetylated – can they be methylated?? Lecture 3: Hallmark discovery and analysis of histone modifications

Evidence 2 **Suv39h genes show high sequence conservation to** a plant gene with **proposed histonemethyltransferase activity**

Identification of H3 Lys9 methyltransferase activity

Experiment:

Overexpression of myc-tagged-SUV39H1 in Hela cells

Use an antibody to immunoprecipitate mycSUV39H1 \rightarrow high concentration of SUV39H1

Incubate Immunopreciptate with purified histones and S-adenosyl- $[methyl-14Cl-1-methionin]$ as methyl donor

• The SET domain of the SUV39H1 is required for histone methyltransferase activity and this enzyme methylates H3 at Lys9 Nature. 2001 Mar 1;410(6824):116-20.

> Methylation of histone H3 lysine 9 creates a binding site for HP1 proteins. Lachner M¹, O'Carroll D, Rea S, Mechtler K, Jenuwein T.

Identification of H3 Lys9 methyltransferase activity

Experiment:

Purify histone H3 by reverse-phase-liquid chromatography after HMTassay

Sequence histone H3 and quantify the amount of radioactivity per ammino acid

Suv39H1 methylates histone H3 at lysine 9

Identification of other Histone H3 Lys9 methyltransferases

- The SET domain is the conserved catalytic core of histone methyltransferases
- The histone H3 tail has 3 sites for methylation at lysines

Identification of other Histone H3 Lys9 methyltransferases

• The SET domain is the conserved catalytic core of histone methyltransferases

SET domain protein have sequence specifcity for pepide sequence around target K

• Mutations of some histone methyltransferases \rightarrow cancer

Post-translational histone modifications can recruit specialized proteins

Problem:

- 1. How can we detect epigenetic modifications?
- -Generation of antibodies that specifically Recognize modified histones (western blotting/Immunofluorescence)
- Mass spectroscopy

Problem:

- 2. How can we locate epigenetic information at defined regions or genes or promoters, etc?
- -*DAPI intense regions; DNA-FISH probes*
- -*Chromatin immunoprecipitation*
- --> Detect histone modifications on specific genomic site of interest (i.e promoter of p53) --> Detect histone modifications at multiple sites or at the entire genome level

1. Generation of antibodies that specifically recognize modified histones

Lysines can be mono-, di- and tri-methyalted An example: H3K9methylation by Suv39h1

 C_{+N}^{H}
 $(C_{+2}^{H})^{H}$
 $(C_{+2}^{H})^{H}$
 D_{+N}^{H} **H3K9-specific** KMT **KMT** KDM **KDM Lysine-HMTases (KMTases) can** $H_3 N^{\prime H}$ COO- \bigcirc COO mediate mono-, di-, tri-methylation Lysine Mono-methyl Di-methyl Tri-methyl Lysine (me1) Lysine (me2) Lysine (me3)

1. Generation of antibodies that specifically recognize modified histones

 \rightarrow \rightarrow resembles high concentration of chromatin modification in the nucleus

Generation of polyclonal/monoclonal antibodies

Polyclonal antibodies can form lattices with homogeneous, monomeric protein antigens because each antibody can interact with a different epitope on the antigen.

Monoclonal antibodies do not form lattices with homogeneous, monomeric proteins, because only they can bind to only one epitope on the antigen.

conjugate

Generation of polyclonal antibodies

& amonium sulfate purification

Most purines are recycled rather than degraded. HGPRT can recycle hypoxanthine and guanine to be used in DNA replication

HAT Medium (hypoxanthine-aminopterin-thymidine medium) is a selection medium for mammalian cell culture, which relies on the combination of aminopterin, a drug that acts as a powerful folate metabolism inhibitor by inhibiting dihydrofolate reductase, with hypoxanthine (a purine derivative) and thymidine (a deoxynucleoside) which are intermediates in DNA synthesis. Its binding affinity for dihydrofolate reductase effectively blocks tetrahydrofolate synthesis. This results in the **depletion of nucleotide precursors** and inhibition of DNA, RNA, and protein synthesis. The trick is that aminopterin blocks DNA de novo synthesis, which is absolutely required for cell division to proceed, but hypoxanthine and thymidine provide cells with the raw material to evade the blockage (the "salvage pathway"), provided that they have the HGPRT gene \rightarrow rescue of DNA replication

HAT medium is often used for preparation of monoclonal antibodies. This process is called Hybridoma technology. Laboratory animals (e.g., mice) are first exposed to an antigen against which we are interested in isolating an antibody. Once splenocytes are isolated from the mammal, the B cells are fused with HGPRT negative, immortalized myeloma cells using polyethylene glycol or the Sendai virus. Fused cells are incubated in the HAT medium. Aminopterin in the medium blocks the de novo pathway. Hence, unfused myeloma cells die, as they cannot produce nucleotides by de novo or salvage pathway. Unfused B cells die as they have a short lifespan. In this way, only the B cellmyeloma hybrids survive. These cells produce antibodies (a property of B cells) and are immortal (a property of myeloma cells). The incubated medium is then diluted into multiwell plates to such an extent that each well contains only 1 cell. Then the supernatant in each well can be checked for desired antibody. Since the antibodies in a well are produced by the same B cell, they will be directed towards the same epitope, and are known as monoclonal antibodies.

Cloning hybridomas from fusion event

1. Plate at limiting dilution (<1 cell/well) in 96 well plates.

- for example: volume per well: 100 microliter

- use fused cells and prepare cell suspession of ca. 1 cell/ml (0,1 cell per100ul well \rightarrow 1 cell every 10 wells)

2. Allow clones to expand in 96 well = cell clone or cell line (a population of hybridoma cells derived from a single cell

 $=$ genetically identical) \rightarrow Hybridoma line

3. Further expand positive well and test for production of antibody of desired specificity in culture supernatant

Cloning hybridomas from fusion event

- 1. Plate at limiting dilution (<1 cell/well) in 96 well plates.
- for example: volume per well: 100 microliter
- use fused cells and prepare cell suspession of ca. 1 cell/ml (0.1 cell per well \rightarrow 1 cell every 10 wells)
- **2. Allow clones to expand in 96 well = cell clone or cell line (a population of hybridoma cells derived from a single cell**

 $=$ genetically identical) \rightarrow Hybridoma line

3. Further expand positive well and test for production of antibody of desired specificity in culture supernatant

-Hybridoma cells secrete antibody into cell culture medium

-Purification of

- antibody
- -Validation of antibody

Validation of antibodies

Validation by dot-blot (pure antigen spotted on membrane)

1. Spot branched peptides at different concentration on membrane

2. Incubate with respective

3. Incubate with secondary Antibody that is coupled with horseradish peroxidase

4. Add substrate for Horseradish peroxidase

Obtaining evidence for the specificity of histone modifying enzymes \rightarrow in cells

or Suv39h1 siRNA

In Suv39h dn cells, H3K9me2 and H3K9me2 are still present. Suv39h1 is a H3K9 specific HMTase that is required to establish the TRI-METHYLATION **of H3K9 in mammalian cells**

Note, that in the absence of H3K9me3, H3K9me1 is localized at DAPI rich regions

2. Studying histone modifications by mass spectrometry

In a typical MS procedure proteins are ionized, for example by bombarding it with electrons. This may cause some of the sample's molecules to break into charged fragments.

These ions are then separated according to their mass-to-charge ratio, typically by accelerating them and subjecting them to an electric or magnetic field:

Ions of the same mass-to-charge ratio will undergo the same amount of deflection. Jons with different mass-to-change ratio will show different deflection

\rightarrow mono-methylated H3K9 has different defection **than di-or tri-methylated H3K9**

The ions are detected by a mechanism capable of detecting charged particles, such as an electron multiplier. Results are displayed as spectra of the relative abundance of detected ions as a function of the mass-to-charge ratio.

The molecules in the sample can be identified by correlating known masses to the identified masses or through a characteristic fragmentation pattern.

MW of all amino acids and all their possible modifications are know = identifiable by mass-to-change ration: also when present in a series of aminoacids

MOST IMPORTANT: provide a sample with defined peptide fragments \rightarrow achieved by digest with **proteases that cut peptides at defined positions** (comparable with restriction enzymes)

2. Studying histone modifications by mass spectrometry

Arows indicate trypsin target sites for cleavage

Histone modifications change m/z ratio in mass spec experiments

For details: An Introduction to Mass Spectrometry

http://www.astbury.leeds.ac.uk/facil/MStut/mstutorial.htm

2. Studying histone modifications by mass spectrosmetry

PROBLEM:

1. Trypsin cleavage after K is not complete because me2 or me3 on some lysines block block cutting by Trypsin

2. K is frequent in histone tails --> result many cleavages (mostly at me0, me1) \rightarrow many small **heterogeneous peptides** \rightarrow **difficult to analyze**

SOLUTION: In vitro Propionylation of unmodified or mono-methylated lysine prevents trypsin cleavage

- \rightarrow now Trypsin can only cut after Arginine.
- \rightarrow this allows a uniform cleavage of histone tails
- \rightarrow creates a mass: charge ratio that allows to differentiate between fragments carrying me0, me1, me2 or $me3$ marks (me0 + 1x propionyl group; me1 + 1x propionyl group; me2 + 0 propionyl group; me3 + 0x propionyl groups)

2. Studying histone modifications by mass spectrometry

TRYPSIN cuts ONLY at Arg by Trypsin after propionylation

Now Trypsin can only cut after Arginine. This allows a uniform cleavage of histone tails

The number of methyl-groups/propinyl groups at the H3 peptide $K9 - R17$ decides on the deflection of this specific peptide in mass spectrometry.

Important: All peptides cut at Arg by Trypsin are analyzed contemporarily!!!!

2. Studying histone modifications by mass spectrometry

2. Studying histone modifications by mass spectrometry

The method allows to quantify the numbers of H3K9me0, H3K9me1 H3K9me2 and H3K9me3 in a sample \rightarrow We can calculate the % of each histone modification in the given sample.

Important: The analysis is not limited to H3K9 \rightarrow **other histone modifications can be quantified in the same analysis**

2. Studying histone modifications by mass spectroscopy

2. Studying histone modifications by mass spectroscopy

The method allows to quantify the numbers of H3K9me0, H3K9me1 H3K9me2 and H3K9me3 in a sample \rightarrow We can calculate the % of each histone modification in the given sample.

Important MS is a proteomics approach: The analysis is not limited to H3K9 \rightarrow all other histone modifications can be quantified in the same analysis. Remember: the histone proteins were isolated prior to MS. This allows also to discover possible regulatory loops between different histone modifications!!! (for this you always **need 2 biologically different samples: genetic model; differentiation, treatment, etc…)**

2. Quantifying histone modifications by mass spectroscopy

Suv39h1 and Suv39h2 ensure H3K9me3. H3K9me1 is a preferred substrate for Suv39h1/h2 Suv39h1/h2 methylate H3K9me1 Until reaching the tri-methylated state

Wild-type Suv39h double null (dn)

2. Quantifying histone modifications by mass spectroscopy

1. Identifying the enzymatic activity of a histone modifying enzymes (LOF of epigenetic writer)

2. Identification of "modifiable" amminoacids in histone tails

3. Functional link between histone modifications

4. Defining the ENTIRE epigenetic status of a cell type (for example: differentiated/stem cell)

5. Quantitative information on histone modifications (%)

HOW CAN EPIGENTIC READERS BE IDENTIFIED?

Identifying methyl-H3 binding proteins

• histone peptide pulldown assay: protein identificiation

What are the target sites for Suv39h1 and H3K9me???

- histone peptide pulldown assay: validation of interaction and functional analysis
- Using the peptide pull-down assay, it was found that Lys9-methylated H3 binds to heterochromatin protein 1 (HP1)

Pull-down assay:

-Couple biotinylated histone tail-peptides, carrying specific modifications (methylated, or unmethylated) to stretptavidine coated resin

-Incubate with recombinant ³⁵S-labelled HP1, produced in E-coli

-Wash resin

-Elute bound proteins, run gel and make radiography

- HP1 is a protein previously identified to be enriched in and important for heterochromatin assembly
- Lys9-methylated H3 binds to HP1 via the chromodomain motif in HP1

Lys9-methylated H3 binds to the conserved motif called chromodomain

Bannister et al, Nature, 2001

What are the target sites for Suv39h1 and H3K9me???

• histone peptide pulldown assay: validation of interaction and functional analysis

Pull-down assay:

-Couple biotinylated histone tail-peptides, carrying specific modifications (methylated, or unmethylated) to stretptavidine coated resin

- **35S-labelled mutant versions of HP1:** Δ**C;** Δ**CS;** Δ**H**

-Wash resin

-Elute bound proteins, run gel and make radiography

Delta C domain (chromodomain) doesn't bind: = binds modified histone tail

Lys9-methylated H3 binds to the conserved motif called chromodomain

Bannister et al, Nature, 2001

Where does Suv39h1 act in a cell ??? IMMUNOFLUORESCENCE à **MACROSCOPIC ANALYSIS** \rightarrow Localization of protein across large regions of DNA

Primary, mouse anti-HP1 + secondary rabbit anti-mouse-Cy3 (emission at 570 nm) Primary, human anti-H3K9me3 + secondary donkey anti-human Alexa 488 (emission at 488 nm)

Over-expression of SUV39H1 in Hela cells causes an accumulation of HP1. Stabilization? Is there a link between $Suv39h1 - H3K9me3$ and $HP1?$?

myc-SUV39H1: myc-epitope tagged Suv39H1

Melcher et al, MCB, 2000

What are the target sites for Suv39h1 and H3K9me???

Another evidence for HP1 and Suv39h interaction came from Drosophlla

- back to early genetics studies in *Drosophila*:
- Su(var) 2-5 (gene) codes for heterochromatin protein 1
- Su(var) 2-5 shows similar phenotype like Su(var)3-9
- HP1 in Drosophila is localized to the chromocenter
SUV39h HMTase activity is important to build constitutive heterochromatin

Loss of Suv39h1 expression results in delocalization of HP1 from chromocenters

Re-expression of Suv39h1 rescues Localization of HP1 to chromocenters

Re-expression of Suv39h1 that Contains an enzymatic dead mutation (H324L) in SET domain does not rescue the localization of HP1 to chromo centers

 \rightarrow The enzymatic activity of Suv39h1 Is required for recruitment of HP1 to chromocenters

Site specific methylation of the H3 tail has different functions

What are the target sites for Suv39h1 and H3K9me???

CHROMATIN IMMUNOPRECIPITATION \rightarrow **DETAILLED ANALYSIS** \rightarrow Localization of protein at a defined region - seqeunce

The combination of Immunoprecipitation methods and PCR analysis allows to define the histone code at defined sequences. **PCR** primers define the site of analysis in the genome

EXAMPLE: Pericentric heterochromatin in mouse cells

A

H3 K9-methylation is required for HP1 localization is required for $\mathbf{H} = \mathbf{H} \mathbf{H}$ **CHROMATIN IMMUNOPRECIPITATION**

B Formaldehyde will crosslink amino or imino groups within 2Å, for example:

CHROMATIN IMMUNOPRECIPITATION

2. Cross linking followed by sonication (fragmentation of chromatin)

Chromatin is bulky \rightarrow needs to be cut into small pieces **to become soluble**

H3 K9-methylation is required for HP1 localization is required for $\mathbf{H} = \mathbf{H} \mathbf{H}$ **CHROMATIN IMMUNOPRECIPITATION**

3. Immunoprecipitation (IP)

The protein of interest is immunoprecipitated together with the crosslinked DNA: Modified histones; epignetic writers, **epigentic readers**

H3 K9-methylation is required for HP1 localization is required for $\mathbf{H} = \mathbf{H} \mathbf{H}$ **CHROMATIN IMMUNOPRECIPITATION**

4.Decrosslinking of PFA crosslinked chromatin and and purification of the DNA

H3 K9-methylation is required for HP1 localization is required for $\mathbf{H} = \mathbf{H} \mathbf{H}$ **CHROMATIN IMMUNOPRECIPITATION**

CHROMATIN IMMUNOPRECIPITATION (ChIP) \rightarrow **DETAILLED ANALYSIS** \rightarrow Localization of protein at a defined region - seqeunce

Cell model system: i.e. Wild-type or Suv39 dn cells that grow in cell culture dish 1. Crosslink chromatin (treatment of cells with Paraformaldehyde

2. Sonicate crosslinkedcells

3. Incubate chromatin fragments with antibodies **raised against H3K9me3**

4. Recover antibody-chromatin complexes using a resin that binds to the constant region of antibodies

5. Elute chromatin at high salt concentration and **revert crosslinks at high temperature**

6. Digest protein with protease K and RNA with RNase

5. Elute chromatin at high salt concentration and **revert crosslinks at high temperature**

6. Digest protein with protease K and RNA with RNase

7. Purify DNA and precipitate DNA

8. Measure the amount of immunoprecipitated DNA **In control versus Suv39h dn cells**

METHODS:

Quantitative PCR: design PCR oligos to amplify defined sequences in immunoprecipitates. Per PCR reaction only one Locus can be examined by real-time PCR

What are the target sites for Suv39h1 and H3K9me???

CHROMATIN IMMUNOPRECIPITATION FOLLOWED BY QUANTITTIVE PCR

Design PCR oligos that amplify major and minor satellite repeats

EXAMPLE: Pericentric heterochromatin in mouse cells

Min/Maj F1...: forward primer in unique region

CHROMATIN IMMUNOPRECIPITATION (ChIP) COUPLED WITH PCR $→$ **H3K9me3** is enriched at pericentric (major+minor) repeats in mouse cells

Major satellite repeats Minor satellite repeats

H3-K9

H3-K9

PCR amplification of major/minor satellite **Repeats after ChiP using Antibodies that are specific for H3K9me1; H3K9me3; H3K9me3**

Suv39h1 is required for imposition of H3K9me3 at pericentric repeats

From molecular data to phenotypes and biological relevance

Lack of SUV39h HMTase activity results in genomic instability

A knock-out model system for Suv39h1 and Suv39h2 - Loss of Suv39h1/2: smaller body size

Fibroblasts from Suv39h1/2 null mice are aneuploidy

Lack of SUV39h HMTase activity results in genomic instability

SUV39h HMTase activity is essential for fidelity in mitosis/meiosis

CHROMATIN IMMUNOPRECIPITATION (ChIP) \rightarrow **DETAILLED ANALYSIS** \rightarrow Localization of protein at a defined region - seqeunce

Cell model system: i.e. Wild-type or Suv39 dn cells that grow in cell culture dish 1. Crosslink chromatin (treatment of cells with Paraformaldehyde

2. Sonicate crosslinkedcells

3. Incubate chromatin fragments with antibodies **raised against H3K9me3**

4. Recover antibody-chromatin complexes using a resin that binds to the constant region of antibodies

5. Elute chromatin at high salt concentration and **revert crosslinks at high temperature**

6. Digest protein with protease K and RNA with RNase

5. Elute chromatin at high salt concentration and **revert crosslinks at high temperature**

6. Digest protein with protease K and RNA with RNase

7. Purify DNA and precipitate DNA

8. Measure the amount of immunoprecipitated DNA **In control versus Suv39h dn cells**

METHODS:

Quantitative PCR: design PCR oligos to amplify defined sequences in immunoprecipitates. Per PCR reaction only one Locus can be examined by real-time PCR

ChIP on ChIP: Analysis of epigenetic information across a high number of genomic sites in the genome

ChIP on ChIP: Analysis of epigenetic information across a high number **of genomic sites in the genome**

ChIP on ChIP: Analysis of epigenetic information across a high number of genomic sites in the genome

ChIP on ChIP: Analysis of epigenetic information across a high number of genomic sites in the genome

targets to determine relative abundance of nucleic acid sequences in the target

ChIP on ChIP: Analysis of epigenetic information across a high number of genomic sites in the genome

Arrays do not contain the entire human/mouse genome Arrays are enriched for particular seqeunces according to experimental need (promoter, enhancer, etc...)

ChIP on ChIP: Analysis of epigenetic information across a high number of genomic sites in the genome

Advantage: low tech, cheap **Disadvantage:** low resolution, no data on number of molecules $-$ just proportions; laborious to reach a good genome coverage

Already outdated \rightarrow state of the art: ChIP seq

ChIP seq: Analysis of epigenetic information on the single nucleotide level \rightarrow GENERATION OF GENOME WIDE EPIGENTIC MAPS

Cell model system: i.e. Wild-type or Suv39 dn cells that grow in cell culture dish 1. Crosslink chromatin (treatment of cells with Paraformaldehyde

2. Sonicate crosslinkedcells

3. Incubate chromatin fragments with antibodies **raised against H3K9me3**

4. Recover antibody-chromatin complexes using a resin that binds to the constant region of antibodies

5. Elute chromatin at high salt concentration and **revert crosslinks at high temperature**

6. Digest protein with protease K and RNA with RNase

5. Elute chromatin at high salt concentration and **revert crosslinks at high temperature**

6. Digest protein with protease K and RNA with RNase

7. Purify DNA and precipitate DNA

8. Measure the amount of immunoprecipitated DNA **In control versus Suv39h dn cells**

METHODS:

Massive parallel sequencing of immunoprecipitated DNA Permits to obtain epigenetic information on the single nucleotide level

ChIP seq: Analysis of epigenetic information on the single nucleotide level \rightarrow GENERASTION OF GENOME WIDE EPIGENTIC MAPS

READY FOR MASSIVE PARALLEL SEQEUNCING

ChIP seq: Analysis of epigenetic information on the single nucleotide level \rightarrow GENERASTION OF GENOME WIDE EPIGENTIC MAPS

Illumina Massively Parallel Sequencing

https://www.illumina.com/company/videohub/pfZp5Vgsbw0.html

The heart of the Illumina Massive Parallel Sequencer is the "FLOW-CELL". A surface with millions of small wells that allow thousands of Sanger-sequencing reaction In parallel = "massive parallel sequencing". In each well a SINGLE MOLECULE of DNA **Is amplified and sequenced**

Illumina offers the most potent massive sequencing instruments –leader on the market

https://www.youtube.com/watch?v=pfZp5Vgsbw0

ChIP seq: Analysis of epigenetic information on the single nucleotide level \rightarrow GENERASTION OF GENOME WIDE EPIGENTIC MAPS

CLUSTER AMPLIFICATION:

Flow cell contains surface with millions of wells

 \rightarrow Each well contains beads mounted with 2 species of oligonucleotides that hybridize with **adaptor oligos of DNA library**

 \rightarrow DNA library will be loaded onto the flow **cell in a determined concentration:**

ONLY ONE MOLECULE OF DNA WILL BE PROCESSED FOR SEQUENCING IN A SINGLE WELL

-making DNA library (~300bp fragments)

-ligation of adapters **A** and **B** to the fragments

- complementary primers are ligated to the surface
- pairing with ChiP ed ssDNA at random position in the well of the flow cell

Bridge amplification: takes place on surface of beads (each bead is mounted with 2 species of oligos; each oligo can hybridize to a DNA library fragment): initiation

On the surface: complementary oligos

REVERSIBLE CHAIN TERMINATORS:

Instead of promoting irreversible primer extension like the Sanger dye terminator method, the reversible chain terminators method uses a cydic method that consists of nucleotide incorporation, fluorescence imaging and cleavage.

The figure shows a modified nucleotide with a **cleavable dye** and **reversible blocking group. Once the blocking group is removed, a 3'OH isformed and a new nucleotide may come in.**

NOTE: no classic dNTPs are used forsequencing!!!!

Procedure

The steps for such a process can be outlined as follows:

- 1. Have four dNTP's, each with a different fluorescent marking. These markings should not interfere with base pairing or phosphodiester bond formation.
- 2. Each dNTP should terminate DNA elongation temporarily with a blocking group on the 3' carbon of the sugar moiety.
- 3. Upon each cycle, have just one dNTP bind to the elongating strand and emit a fluorescent dye color.
- 4. Depending on the color emitted, record the particular nucleotide.
- 5. Cleave the blocking group and fluorescent dye with a palladium-catalyst.
- 6. Restore a 3' hydroxyl so that the growing strand can now elongate.
- 7. Repeat from step 1.

Cons

There are some limitations to this method which include:

- Incomplete cleavage of blocking groups.
- Difficulties incorporating fluorescent nucleotides.

Three different 3'-blocked reversible terminators were shown on the left (A–C) and two 3'-unblocked reversible terminators were shown on the right $(D-E)$.

The chemical structures in red denote the reversible terminating groups. Arrows indicate the site of cleavage separating the fluorescent groups from the nucleotide, and the chemical structures in blue denote the molecular scars that are attached to the base.

Illumina: massive parallel sequencing:

- **1.** Start of synthesis using primer = incorporation of fluorescent 3'blocked reversible terminator: **synthesis blocked**
- **2.** Scanning of fluorescent signals of all wells of flow-cell with laser (image)
- **3.** Dye cleavage + elimination of reversible blocking group
- **4. wash step**
- **1. Repeat steps 1-4 ca. 150x**

READ LENGTH: ca: 150nt from each primer (2x150nt = 300nt)

Illumina Sequencing Technology *Robust Reversible Terminator Chemistry Foundation*

In each round of sequencing a fluorescently labelled ddNTPwill be used for sequencing. ddATPcarries different fluorphor than ddTTP, etc..

Illumina: paired end sequencing increases information content

Figure 1-2-1 Pipeline of paired-end sequencing (www.illumina.com)

https://www.youtube.com/watch?v=9YxExTSwgPM

Data analysis: obtained sequence reads are aligned along genomic DNA sequence \rightarrow high number of reads necessary to obtain **full sequence coverage**

Sequence derived from one amplified cluster

PILE – UP ALIGNEMENT ACROSS THE REFERENCE GENOME

Data analysis: obtained sequence reads are aligned along genomic DNA sequence \rightarrow high number of reads necessary to obtain full sequence coverage

Reference genome

BIOINFORMATICS ANALYSIS: Mapping ChIP seq reads agins the human genomic sequence

Goldberg et al., Cell, 140: 678-691. 2010

Mapping the epigenetic landscape enables to define "key rules" to define the epigenetic code of active and silent genes

